HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.

Abstract
Nanoparticulate delivery systems for vaccine adjuvants, designed to enhance targeting of secondary lymphoid organs and activation of APCs, have shown substantial promise for enhanced immunopotentiation. We investigated the adjuvant activity of synthetic oligonucleotides containing CpG-rich motifs linked to the sucrose polymer Ficoll, forming soluble 50-nm particles (DV230-Ficoll), each containing >100 molecules of the TLR9 ligand, DV230. DV230-Ficoll was evaluated as an adjuvant for a candidate vaccine for anthrax using recombinant protective Ag (rPA) from Bacillus anthracis. A single immunization with rPA plus DV230-Ficoll induced 10-fold higher titers of toxin-neutralizing Abs in cynomolgus monkeys at 2 wk compared with animals immunized with equivalent amounts of monomeric DV230. Monkeys immunized either once or twice with rPA plus DV230-Ficoll were completely protected from challenge with 200 LD50 aerosolized anthrax spores. In mice, DV230-Ficoll was more potent than DV230 for the induction of innate immune responses at the injection site and draining lymph nodes. DV230-Ficoll was preferentially colocalized with rPA in key APC populations and induced greater maturation marker expression (CD69 and CD86) on these cells and stronger germinal center B and T cell responses, relative to DV230. DV230-Ficoll was also preferentially retained at the injection site and draining lymph nodes and produced fewer systemic inflammatory responses. These findings support the development of DV230-Ficoll as an adjuvant platform, particularly for vaccines such as for anthrax, for which rapid induction of protective immunity and memory with a single injection is very important.
AuthorsMelissa A Kachura, Colin Hickle, Sariah A Kell, Atul Sathe, Carlo Calacsan, Radwan Kiwan, Brian Hall, Robert Milley, Gary Ott, Robert L Coffman, Holger Kanzler, John D Campbell
JournalJournal of immunology (Baltimore, Md. : 1950) (J Immunol) Vol. 196 Issue 1 Pg. 284-97 (Jan 01 2016) ISSN: 1550-6606 [Electronic] United States
PMID26608924 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
CopyrightCopyright © 2015 by The American Association of Immunologists, Inc.
Chemical References
  • Adjuvants, Immunologic
  • Anthrax Vaccines
  • Antigens, Bacterial
  • Antigens, CD
  • Antigens, Differentiation, T-Lymphocyte
  • B7-2 Antigen
  • Bacterial Toxins
  • CD69 antigen
  • Lectins, C-Type
  • Oligonucleotides
  • Recombinant Proteins
  • Vaccines, Synthetic
  • anthrax toxin
  • Ficoll
Topics
  • Adjuvants, Immunologic (administration & dosage)
  • Animals
  • Anthrax (immunology, microbiology, prevention & control)
  • Anthrax Vaccines (administration & dosage, immunology)
  • Antigens, Bacterial (genetics, immunology)
  • Antigens, CD (biosynthesis)
  • Antigens, Differentiation, T-Lymphocyte (biosynthesis)
  • B-Lymphocytes (immunology)
  • B7-2 Antigen (biosynthesis)
  • Bacillus anthracis (immunology, pathogenicity)
  • Bacterial Toxins (genetics, immunology)
  • Dendritic Cells (immunology)
  • Ficoll (immunology)
  • GC Rich Sequence (genetics)
  • Lectins, C-Type (biosynthesis)
  • Macaca fascicularis
  • Macrophages (immunology)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Nanoparticles
  • Neutrophils (immunology)
  • Oligonucleotides (genetics, immunology)
  • Recombinant Proteins (immunology)
  • Respiratory Tract Infections (immunology, microbiology, prevention & control)
  • T-Lymphocytes (immunology)
  • Vaccination
  • Vaccines, Synthetic (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: